Chennai, Dec. 13 -- Highlights: ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

ACIP votes to change hep B vaccination for infants; positive results for retatrutide; Omisirge approved; counterfeit Ozempic seized by FDA; gene therapy ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Major stock indexes ended mixed Thursday, with the Dow Jones Industrial Average and S&P 500 closing at record highs but the ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

U.S. pharmaceutical company Eli Lilly announced on the 11th that its investigational obesity treatment ‘retatrutide’ demonstrated significant weight loss efficacy in phase 3 clinical trials. In the ...

The Financial Times covers key stories including Lululemon CEO Calvin McDonald's departure, crypto founder Do Kwon's prison sentence, Disney's $1 billion investment in OpenAI, and the end of ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...